These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16929517)

  • 21. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.
    Chung-Faye G; Hayee B; Maestranzi S; Donaldson N; Forgacs I; Sherwood R
    Inflamm Bowel Dis; 2007 Nov; 13(11):1374-8. PubMed ID: 17577247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of tumor pyruvate kinase M2 isoform in plasma and stool of patients with colorectal cancer or adenomatous polyps.
    Rigi F; Jannatabad A; Izanloo A; Roshanravan R; Hashemian HR; Kerachian MA
    BMC Gastroenterol; 2020 Jul; 20(1):241. PubMed ID: 32727566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic Value of Pyruvate Kinase Isoenzyme Type M2 in Colon Cancer Proven with Colonoscopy.
    Kalantari H; Khodadoostan M; Yaran M; Tavakoli A
    Adv Biomed Res; 2020; 9():76. PubMed ID: 33912492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening.
    Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
    Anticancer Res; 2003; 23(2A):855-7. PubMed ID: 12820313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls.
    Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
    Anticancer Res; 2003; 23(2A):851-3. PubMed ID: 12820312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Power of screening tests for colorectal cancer enhanced by high levels of M2-PK in addition to FOBT.
    Zaccaro C; Saracino IM; Fiorini G; Figura N; Holton J; Castelli V; Pesci V; Gatta L; Vaira D
    Intern Emerg Med; 2017 Apr; 12(3):333-339. PubMed ID: 28155016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention.
    Koss K; Maxton D; Jankowski JA
    Colorectal Dis; 2008 Mar; 10(3):244-8. PubMed ID: 17784868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stool test for colorectal cancer screening--it's time to move!
    Loitsch SM; Shastri Y; Stein J
    Clin Lab; 2008; 54(11-12):473-84. PubMed ID: 19216253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders.
    Jeffery J; Lewis SJ; Ayling RM
    Inflamm Bowel Dis; 2009 Nov; 15(11):1630-4. PubMed ID: 19462434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparison of different stool tests for the detection of cancer of the colon].
    Vogel T; Driemel C; Hauser A; Hansmann A; Lange S; Jonas M; Möslein G
    Dtsch Med Wochenschr; 2005 Apr; 130(14):872-7. PubMed ID: 15800820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Faecal biomarkers do not always identify pre-cancerous lesions in patients who present in primary care with bowel symptoms.
    Keenan J; Aitchison A; Leaman J; Pearson J; Frizelle F
    N Z Med J; 2019 Aug; 132(1501):48-56. PubMed ID: 31465327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort.
    Leen R; Seng-Lee C; Holleran G; O'Morain C; McNamara D
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):514-8. PubMed ID: 24699725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fecal tumor M2 pyruvate kinase is not a specific biomarker for colorectal cancer screening.
    Shastri YM; Stein J
    World J Gastroenterol; 2007 May; 13(19):2768-9. PubMed ID: 17569153
    [No Abstract]   [Full Text] [Related]  

  • 34. KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer.
    Battaglia P; Baritono E; Remo A; Vendraminelli R; Conti A
    Tumori; 2014; 100(2):122-7. PubMed ID: 24852854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Use of M2-Pyruvate Kinase as a Stool Biomarker for Detection of Colorectal Cancer in Tertiary Teaching Hospital: A Comparative Study.
    Che Alhadi S; Wan Zain WZ; Zahari Z; Md Hashim MN; Syed Abd Aziz SH; Zakaria Z; Wong MP; Zakaria AD
    Ann Coloproctol; 2020 Dec; 36(6):409-414. PubMed ID: 32972105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of faecal protein biomarkers' diagnostic accuracy for colorectal advanced neoplasms: a systematic review and meta-analysis.
    Nasir Kansestani A; Zare ME; Tong Q; Zhang J
    Sci Rep; 2022 Feb; 12(1):2623. PubMed ID: 35173276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation between Faecal Tumour M2 Pyruvate Kinase and Colonoscopy for the Detection of Adenomatous Neoplasia in a Secondary Care Cohort.
    Bond AD; Burkitt MD; Sawbridge D; Corfe BM; Probert CS
    J Gastrointestin Liver Dis; 2016 Mar; 25(1):71-7. PubMed ID: 27014756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of Faecal Pyruvate Kinase Isoenzyme Type M2 (Faecal M2PK Quick) Test in Detection of Colorectal Adenoma and Adenocarcinoma Among High-Risk Malaysian Population.
    Mohd Suan MA; Ng YZ; Henry GF; Md Said R; Kollanthavelu S; Mustapha MI; Hoe CH; Lee CK; Rajamanickam P; Ismail I; Chan HK; Abu Hassan MR
    Asian Pac J Cancer Prev; 2023 Sep; 24(9):3183-3186. PubMed ID: 37774070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pilot study on M2-PK-- a new non-invasive parameter for early diagnosis of colorectal carcinoma].
    Ivanova A; Iarŭmov N; Toshev S; Adzharov D; Krŭstev Z; Angelov K; Sokolov M; Gribnev P
    Khirurgiia (Sofiia); 2007; (6):5-7. PubMed ID: 18622373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumour M2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults vs colorectal cancer patients.
    Haug U; Rothenbacher D; Wente MN; Seiler CM; Stegmaier C; Brenner H
    Br J Cancer; 2007 May; 96(9):1329-34. PubMed ID: 17406361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.